Join the Esophageal Carcinoma group to help and get support from people like you.
Esophageal Carcinoma News
FDA Approves Hercessi (trastuzumab-strf), a Biosimilar to Herceptin
DURHAM, N.C., April 29, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
FDA Approves Tevimbra (tislelizumab-jsgr) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug...
Scientists Spot Gene Mutation Linked to Esophageal Cancer
FRIDAY, Sept. 22, 2023 – Researchers have found a gene mutation linked to esophageal cancer, which could lead to better prevention and treatment strategies. Investigators from Case Western Reserve...
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
MONDAY, Aug. 28, 2023 – The Kettles Esophageal and Cardia Adenocarcinoma predictioN (K-ECAN) Tool can predict incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) using...
One-Fourth of Esophageal Cancers Among Those With BE Missed in Year Before Diagnosis
FRIDAY, Aug. 4, 2023 – Nearly one-quarter of Barrett esophagus patients with esophageal adenocarcinoma (EAC) had normal endoscopic screenings within the prior year, according to a study published...
U.S. Food and Drug Administration Approves Two Opdivo (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Opdivo in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) approved based on a Phase 3 trial showing improved overall survival versus chemotherapy alone1,2 Opdivo-based ...
FDA Approves Opdivo (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE) May 20, 2021 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab, injection for ...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) March 23, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
PRINCETON, N.J.--(BUSINESS WIRE) June 10, 2020 Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment...
FDA Approves Keytruda (pembrolizumab) for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
KENILWORTH, N.J.--(BUSINESS WIRE) July 31, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin
March 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the ...
Ask a question
To post your own question to this support group, sign in or create an account.